Related by context. All words. (Click for frequent words.) 71 acute coronary syndromes 70 rFVIIa 69 stable angina 69 acute myocardial infarction AMI 69 acute coronary syndrome 69 NATRECOR R 69 thrombolytic agents 68 atherothrombotic disease 68 patients undergoing percutaneous 68 thromboembolic events 68 ischemic complications 67 ximelagatran 67 composite endpoint 67 coronary intervention 67 invasive candidiasis 67 antithrombotics 67 APTIVUS r 67 thromboembolic 67 postoperative AF 67 unstable angina UA 67 thromboembolism 66 invasive aspergillosis 66 recurrent glioblastoma multiforme 66 ARIXTRA 66 Erythropoietic therapies may 66 relapsed refractory multiple myeloma 66 mycophenolate mofetil 66 thrombotic events 66 myocardial infarction stroke 66 olmesartan 66 lipid lowering agents 66 AA Amyloidosis 66 heparin induced thrombocytopenia 66 atherothrombosis 66 ACTEMRA TM 65 aspirin clopidogrel 65 non valvular atrial 65 infarction NSTEMI 65 clevidipine 65 NYHA Class III 65 tolvaptan 65 tumor lysis syndrome 65 NYHA Class II 65 unfractionated heparin UFH 65 superficial bladder cancer 65 ARCOXIA 65 Thrombolysis 65 NSTE ACS 65 secondary hyperparathyroidism 65 irbesartan 65 ATACAND 65 relapsed MM 65 Acute Coronary Syndromes 65 CIMZIA TM certolizumab pegol 65 metastatic renal cell carcinoma 65 DAPT 65 upper gastrointestinal bleeding 65 antithrombotic therapy 65 sunitinib malate 65 tanespimycin 65 vWD 65 complement inhibitor eculizumab 65 ischemic cardiomyopathy 65 castrate resistant prostate cancer 64 gastrointestinal perforation 64 Doxil ® 64 pheochromocytoma 64 cerebrovascular events 64 recurrent GBM 64 Valsartan 64 atherothrombotic events 64 dabigatran etexilate 64 Acute Coronary Syndromes ACS 64 CYPHER Stent 64 HBeAg negative patients 64 symptomatic BPH 64 chemotherapy induced neutropenia 64 IV NSCLC 64 TEAEs 64 thromboembolic complications 64 β blockers 64 hematologic disorders 64 ADHF 64 CANCIDAS 64 GW# [003] 64 DOXIL 64 adult chronic ITP 64 MGd 64 NMIBC 64 BARACLUDE ® 64 clopidogrel Plavix 64 HeFH 64 MYCAMINE 64 INCB# [003] 64 angiographic outcomes 64 refractory AML 64 fluvastatin 64 FluCAM arm 64 tipranavir r 64 vandetanib 64 Pemetrexed 64 dyslipidaemia 64 LV dysfunction 64 recurrent ischemia 64 non metastatic osteosarcoma 64 tipranavir ritonavir 64 patients undergoing CABG 64 ribavirin RBV 64 Acute Ischemic Stroke 64 metastatic GIST 64 metastatic malignant melanoma 64 cytopenias 64 HIV HCV coinfected 64 riociguat 64 heavily pretreated 64 biliary tract cancer 64 hypercholesterolaemia 64 unstable angina pectoris 64 posaconazole 64 systemic fungal infections 64 Venous thromboembolism 64 RE LY ® 64 myelodysplastic syndrome MDS 64 UA NSTEMI 64 recurrent VTE 64 CYPHER ® Stent 64 recurrent DVT 64 rosuvastatin #mg 64 leukemia AML 64 idraparinux 63 LEXIVA r 63 LHRH antagonists 63 evaluating REVLIMID 63 GP IIb IIIa inhibitors 63 atrial fibrillation AF 63 diabetic neuropathic pain 63 oral Hycamtin 63 hepatorenal syndrome 63 Sezary syndrome 63 Amrubicin 63 salmeterol fluticasone 63 mRCC 63 Acute coronary syndromes 63 Navelbine ® 63 INTEGRILIN R 63 pulmonary arterial hypertension PAH 63 thiazide diuretic 63 thromboprophylaxis 63 infarction STEMI 63 prednisone prednisolone 63 ST elevation myocardial 63 overt nephropathy 63 desvenlafaxine succinate 63 CYPHER R Sirolimus eluting 63 antiangiogenic therapy 63 reinfarction 63 relapsing multiple sclerosis 63 DU #b 63 Val HeFT 63 nicardipine 63 azacitidine 63 RAPAFLO R 63 placebo controlled clinical 63 vinorelbine 63 tirofiban 63 aflibercept VEGF Trap 63 active comparator 63 systolic hypertension 63 familial amyloidotic polyneuropathy FAP 63 vasospasm 63 antiepileptic drugs AEDs 63 MULTAQ 63 advanced hepatocellular carcinoma 63 prospective multicenter study 63 malignant neoplasms 63 intracerebral hemorrhage ICH 63 sorafenib Nexavar 63 myocardial ischemia 63 stage IIIB 63 galiximab 63 Navelbine 63 octreotide LAR 63 carotid endarterectomy CEA 63 STEMI ST 63 HBeAg positive patients 63 CYT# potent vascular disrupting 63 cSSSI 63 cardiac dysfunction 63 antiplatelet agents 63 Keppra R 63 myocardial infarction ventricular fibrillation 63 placebo controlled Phase III 63 mixed hyperlipidemia 63 pan HDAC inhibitor 63 intracranial hemorrhage ICH 63 thrombolytics 63 milrinone 63 oral anticoagulation 63 thrombocytopenic 63 eculizumab 63 aldosterone antagonists 63 occlusion PAO 63 Toxicities 63 myocardial infarction MI 63 thrombotic complications 63 CIMZIA ™ 63 thetreatment 63 PAOD 63 HBeAg negative 63 relapsed multiple myeloma 63 TORISEL 63 arterial thromboembolic events 63 biologic DMARD 63 NATRECOR ® 63 extrapyramidal symptoms 63 XIENCE V PROMUS Stent 63 terlipressin 63 Dacogen injection 63 adalimumab Humira 63 angina pectoris 63 antiemetics 62 alpha interferons 62 metastatic neuroendocrine tumors 62 TMC# r 62 urolithiasis 62 cell lymphoma CTCL 62 OZURDEX ® 62 VAPRISOL 62 trials RCTs 62 antiarrhythmic drug 62 receptor tyrosine kinase inhibitor 62 KRAS mutations occur 62 malignant pleural mesothelioma 62 chlorambucil 62 segment elevation myocardial 62 recurrent glioma 62 myelofibrosis polycythemia vera 62 concomitant medications 62 inhibitor RG# 62 Vaprisol 62 PEGylated interferon beta 1a 62 Traficet EN 62 systemic embolism 62 mcg QD 62 drotrecogin alfa activated 62 mixed dyslipidemia 62 cirrhotic patients 62 vincristine doxorubicin 62 pegylated interferon alfa 2b 62 venous thromboembolic events 62 delayed CINV 62 cilengitide 62 bendamustine 62 nadolol 62 hypercalcemia 62 unstable angina 62 sirolimus eluting stent 62 pulmonary hypertension PH 62 mycosis fungoides 62 calcineurin inhibitor 62 refractory gout 62 direct thrombin inhibitors 62 erlotinib Tarceva ® 62 argatroban 62 hepatocellular carcinoma HCC 62 eosinophilic asthma 62 bevacizumab Avastin ® 62 Systemic Lupus Erythematosus SLE 62 nonrandomized 62 nosocomial pneumonia 62 Acute Coronary Syndrome 62 metastatic hormone refractory 62 TAXUS Stent 62 RoACTEMRA 62 paroxysmal AF 62 primary percutaneous coronary 62 renal insufficiency 62 Rheumatoid Arthritis RA 62 VIDAZA 62 paroxetine Paxil 62 TMP SMX 62 cilostazol 62 proliferative diabetic retinopathy 62 relapsing remitting MS RRMS 62 partial onset seizures 62 SJIA 62 immunomodulatory therapy 62 tamoxifen Nolvadex ® 62 Neutropenia 62 nonfatal myocardial infarction MI 62 Hepatocellular Carcinoma HCC 62 Atacand 62 TRITON TIMI 62 periprocedural 62 PREZISTA r 62 acute ischemic stroke 62 prostate cancer CaP 62 stroke myocardial infarction 62 ZOLINZA 62 opioid induced constipation OIC 62 myeloproliferative neoplasms 62 angiotensin receptor blocker ARB 62 doxorubicin docetaxel 62 symptomatic intracranial 62 antiplatelet agent 62 atherothrombotic 62 receiving VELCADE 62 overactive bladder syndrome 62 morphometric vertebral fractures 62 unstable angina chest 62 stable angina pectoris 62 elotuzumab 62 boosted protease inhibitor 62 variceal bleeding 62 Critical Limb Ischemia CLI 62 VELCADE melphalan 62 Angiox R 62 liposomal amphotericin B 62 Fluid retention 62 Myocardial Infarction Study 62 nonmetastatic prostate cancer 62 hyperphenylalaninemia HPA due 62 PSVT 62 recombinant tissue plasminogen 62 hematologic toxicity 62 antithrombotic 62 Hypotension 62 Ischemic 62 IIIa inhibitor 62 revascularization procedures 62 long acting bronchodilator 62 INVEGA ® 62 sJIA 62 constipation OIC 62 peripheral arterial occlusive disease 62 arterial thrombosis 62 metaglidasen 62 chronic immune thrombocytopenic 62 decompensated heart failure 62 cardiovascular hospitalization 62 Acute Myocardial Infarction 62 valsartan 62 STRIDE PD 62 ACUITY trial 62 FOLFOX4 62 sunitinib Sutent 62 MabCampath 62 candidemia 62 thrombotic diseases 62 pertuzumab 62 rosuvastatin Crestor 62 primary hyperparathyroidism 62 carotid artery stenting CAS 62 docetaxel Taxotere ® 62 investigational monoclonal antibody 62 mitoxantrone 62 venous thromboembolism VTE 62 ancrod 62 venous thromboembolic disease 61 extracranial 61 Elitek 61 catheter occlusion 61 protease inhibitor PI 61 haloperidol Haldol 61 Acute Decompensated Heart Failure 61 recurrent myocardial infarction 61 hemorrhagic complications 61 glioblastoma multiforme GBM 61 T2DM 61 chronic thromboembolic pulmonary 61 enalapril 61 TAXUS TM 61 ARCALYST ® 61 nasopharyngitis headache 61 occlusive disease 61 nonischemic 61 cardio renal 61 infusional 61 vaso occlusive crisis 61 phase IIb clinical 61 Events MACE 61 eplerenone 61 benazepril 61 MACCE 61 diabetic peripheral neuropathy 61 idiopathic thrombocytopenic purpura ITP 61 metastatic malignant 61 antihypertensive therapy 61 hematological malignancy 61 diabetic nephropathy 61 acute STEMI 61 fibrinolysis 61 pulmonary embolism PE 61 macrovascular events 61 TEMODAL 61 febrile neutropenia 61 Infusion Reactions Severe 61 dopaminergic therapy 61 Vascugel ® 61 double blinded placebo 61 symptomatic VTE 61 mapatumumab 61 NYHA functional class 61 romiplostim 61 ventricular arrhythmia 61 Natalizumab 61 REMICADE ® 61 histologies 61 myeloproliferative disorders 61 hypercholesterolemia 61 paroxysmal atrial fibrillation 61 Myelofibrosis 61 dacarbazine 61 myocardial infarctions 61 ORENCIA ® 61 undergoing percutaneous coronary 61 haematologic 61 CTEPH 61 myopathy rhabdomyolysis 61 androgen deprivation 61 Hematologic 61 coronary revascularization 61 rebleeding 61 evaluating tivozanib 61 severe hypoglycemic 61 melphalan prednisone 61 infliximab Remicade 61 receiving VICTRELIS 61 cetuximab Erbitux ® 61 thromboses 61 PRADAXA 61 pericardial effusion 61 plasma kallikrein inhibitor 61 haematological malignancies 61 neovascular diseases 61 arterial thromboembolic 61 either acutely decompensated 61 Zometa zoledronic acid 61 left ventricular dysfunction 61 RE LY 61 Myelodysplastic Syndrome MDS 61 lopinavir r arm 61 postoperative atrial fibrillation 61 ALGRX 61 dose cytarabine 61 Neulasta ® 61 HER2 positive metastatic breast 61 Cutaneous T 61 deep venous thromboses 61 painful diabetic neuropathy 61 renal denervation 61 somatostatin analogue 61 beta blockers ACE inhibitors 61 herpetic keratitis 61 micafungin 61 ELOXATIN 61 INVANZ 61 Angiox ® 61 paclitaxel Taxol 61 hemodialysis patients 61 edoxaban 61 corticosteroid therapy 61 ZYVOX 61 mTOR inhibitors 61 lipid lowering drugs 61 hepatic failure 61 recurrent malignant glioma 61 aplastic anemia AA 61 acute gout 61 tipranavir 61 carotid artery stenting 61 gastrointestinal toxicities 61 pancreatic NET 61 EURIDIS 61 lacosamide 61 AVONEX ® 61 SUTENT 61 Glypromate 61 Lenalidomide 61 levosimendan 61 preserved LVEF 61 osteoporotic compression fractures 61 portal vein thrombosis 61 blinded randomized placebo controlled 61 Myelodysplastic syndromes MDS 61 rt PA 61 recurrent venous thromboembolism 61 preserved ejection fraction 61 TYKERB 61 atrial arrhythmias 61 angiotensin converting enzyme inhibitors 61 SNRI 61 Tyrima 61 pancreatic adenocarcinoma 61 EFFEXOR XR 61 nephrotoxicity 61 idarubicin 61 necrotizing pancreatitis 61 efalizumab 61 standard chemotherapy regimen 61 lactic acidosis 61 bypass graft CABG surgery 61 OHR/AVR# 61 pain palliation 61 placebo dexamethasone 61 Folfox 61 acute leukemias 61 Proxinium TM 61 somatostatin analog 61 anti angiogenic agents 61 antiepileptics 61 VIIBRYD 61 intracerebral haemorrhage 61 coronary lesions 61 failure ADHF 61 Mitoxantrone 61 pegylated liposomal doxorubicin 61 Clolar ® 61 clazosentan 61 lipid parameters 61 neurological manifestations 61 icatibant 61 systemic lupus erythematosus 61 multivessel disease 61 IFN alfa 61 ELACYT 61 GnRH agonists 61 peritumoral brain edema 61 dyslipidemia 61 TTF Therapy 61 thromboembolic disease 61 nondiabetic patients 61 paricalcitol 61 BENICAR 61 aldosterone antagonist 61 oblimersen 61 lomitapide 61 metastatic RCC 61 SCH # 61 chronic myeloid 61 esophageal candidiasis 61 severe hypersensitivity reactions 61 chronic GVHD 61 fondaparinux 61 AEGR 61 BENICAR HCT 61 homozygous familial hypercholesterolemia 61 Torsades de Pointes 61 Keppra ® 61 kidney urologic 61 Tarceva TM 61 CIMZIA TM 61 YONDELIS 61 cerebrovascular accidents 61 hour bronchodilation 61 recurrent NSCLC 61 Angioedema 61 #mg QD [001] 61 ocular adverse 61 null responder HCV 61 cobiprostone 61 4mg/kg 61 INTEGRILIN 61 voriconazole 61 investigational antiplatelet agent 61 CTAP# Capsules 61 Subarachnoid hemorrhage 61 cisplatin gemcitabine 61 assessing T DM1 61 platelet inhibitor 61 dasatinib Sprycel ® 61 relapsing remitting multiple sclerosis 61 Azedra 61 CsA 60 cinacalcet 60 EGFR HER2 60 Renal Cell Carcinoma RCC 60 essential thrombocythemia ET 60 relapsed SCLC 60 MADIT CRT trial 60 lymphoid malignancies 60 T1DM 60 thiazolidinedione 60 Castration Resistant Prostate Cancer 60 insulin detemir 60 HES CEL 60 palonosetron 60 EXJADE 60 Fludara 60 flutamide 60 cediranib 60 candesartan 60 plus gemcitabine 60 Vidaza azacitidine 60 glycated hemoglobin levels 60 SCCHN 60 polycythemia vera essential thrombocythemia 60 post thrombotic syndrome 60 goserelin 60 chronic periodontitis 60 nonobstructive CAD 60 recurrent glioblastoma 60 antiplatelet therapies 60 hematologic malignancies 60 definite stent thrombosis 60 adriamycin 60 gastrointestinal stromal tumors GIST 60 protease inhibitors PIs 60 systolic dysfunction 60 TAXUS Liberte Stent 60 prucalopride 60 myelodysplastic myeloproliferative diseases 60 xanthine oxidase inhibitor 60 reteplase 60 papillary renal cell carcinoma 60 HCV RESPOND 2 60 tocilizumab 60 Neulasta R 60 AGHD 60 COPD exacerbation 60 hyperkalemia 60 AGGRASTAT R 60 neutropaenia 60 diabetic gastroparesis 60 rilonacept 60 oral rivaroxaban 60 daunorubicin 60 colorectal liver metastases 60 vidofludimus 60 undergoing coronary artery 60 neutropenia dehydration dyspnea 60 mitomycin 60 Catena ® 60 eptifibatide 60 standard chemotherapy regimens 60 Chronic Heart Failure 60 mcg BID 60 cSSSIs 60 palliative radiotherapy 60 juvenile idiopathic arthritis 60 gefitinib Iressa 60 sunitinib 60 tenecteplase 60 fibrinolytic therapy 60 paclitaxel eluting stents 60 oropharyngeal candidiasis 60 QTc prolongation 60 Nilotinib 60 oral FTY# 60 velafermin 60 pancreatic carcinoma 60 macrovascular disease 60 Tekamlo 60 Percutaneous Coronary Intervention 60 PegIntron 60 Diabetic nephropathy 60 sorafenib tablets 60 lenalidomide dexamethasone 60 valvular disease 60 idursulfase 60 phase IIb trial 60 REG1 60 lexidronam injection 60 post herpetic neuralgia PHN 60 naïve HCV 60 candesartan cilexetil 60 anticoagulant warfarin 60 acute PAO 60 inhaled bronchodilators 60 claudication 60 intracerebral hemorrhage 60 antithrombotic therapies 60 teriflunomide 60 heterozygous FH 60 NeuroStar TMS Therapy 60 tachyarrhythmias 60 gemcitabine Gemzar 60 calcineurin inhibitors 60 visilizumab 60 antiarrhythmic drugs 60 Torisel 60 VaD 60 Diabetic Macular Edema 60 RhuDex ® 60 Lactic acidosis 60 TNF antagonist 60 opioid analgesia 60 lymphopenia 60 venous thromboembolisms 60 Diabetic Macular Edema DME 60 unfractionated heparin 60 Myocardial Infarction 60 Cloretazine 60 intravenous cyclophosphamide 60 Secondary efficacy endpoints 60 decitabine 60 sorafenib Nexavar ® 60 oral diclofenac 60 angiotensin receptor blockers 60 mycophenolate mofetil MMF 60 TAXUS Express Stent 60 severe exacerbations 60 induced macular edema 60 induce orthostatic hypotension 60 COU AA 60 canakinumab 60 symptomatic paroxysmal AF 60 otamixaban 60 COPAXONE R 60 sodium thiosulfate STS 60 histone deacetylase HDAC inhibitor 60 ß blockers 60 Telmisartan 60 Jevtana 60 CMV disease 60 cardiac repolarization 60 Combo Stent 60 prokinetic agent 60 Sudhir Agrawal D.Phil 60 temsirolimus 60 #mg BID [001] 60 pamidronate 60 Rebif ® 60 nonfatal MI 60 NSAID induced 60 thalidomide Thalomid 60 unfavorable cytogenetics 60 virologic failure 60 Nesiritide 60 metastatic CRC 60 Acute MI 60 chronic HCV infection 60 progressive dyspnea 60 NAVISTAR R 60 idiopathic pulmonary fibrosis IPF 60 lupus nephritis 60 drug zotarolimus 60 liver resection 60 antithrombotic agents 60 prospective randomized controlled 60 octreotide 60 embolic stroke 60 ON #.Na 60 Flu Cy 60 metformin sulfonylurea 60 intermittent claudication 60 venous thromboembolism 60 infarctions 60 Combination therapy 60 MACUGEN 60 Serious adverse reactions 60 plasma uric acid 60 recurrent genital herpes 60 bezafibrate 60 unresectable stage 60 chemoradiotherapy 60 TAXUS V 60 pegylated interferon alpha 60 revascularisation 60 post herpetic neuralgia 60 metastatic HRPC 60 peginterferon alfa 2a 60 Pyridorin 60 oral anticoagulant 60 denileukin diftitox 60 sirolimus eluting stents 60 Factor Xa inhibitors 60 Warfarin Coumadin 60 Acute Myocardial Infarction AMI 60 MabThera rituximab 60 acute coronary 60 TG MV 60 peripheral sensory neuropathy 60 bortezomib Velcade R 60 Epratuzumab 60 rituximab Rituxan ® 60 multicenter Phase III 60 myelodysplastic syndromes MDS 60 anterior uveitis 60 MICARDIS ® 60 investigational compounds 60 SCIg 60 Pegasys ® 60 refractory CTCL 60 bivalirudin 60 atherosclerotic disease 60 atherogenic dyslipidemia 60 virologic breakthrough 60 refractory NSCLC 60 Surgical resection 60 acute decompensated heart 60 alefacept 60 COREG 60 refractory CLL 60 anti arrhythmic drug 60 proliferative retinopathy 60 ularitide 60 solid organ transplantation 60 receiving highly emetogenic 60 cardioembolic stroke 60 coronary stenosis 60 muraglitazar 60 vinca alkaloid 60 myocardial infarction 60 bisoprolol 60 Dacogen decitabine 60 relapsed ovarian cancer 60 severe hypercholesterolemia 60 Trandolapril 60 ALN HPN 60 hepatic encephalopathy HE 60 IFN beta 60 TroVax ® 60 lipid disorders 60 Dasatinib 60 Aspergillus infections 60 acute peripheral arterial 60 invasive fungal infections 60 ruboxistaurin 60 metastatic castration resistant 60 ceftazidime 60 pyridostigmine 60 Adjunctive 60 colorectal adenoma 60 transplantation HSCT 60 osteoarthritis rheumatoid arthritis 60 esophagogastric 60 Acute Myelogenous Leukemia AML 60 6R BH4 60 hyperprolactinemia 60 neoadjuvant 60 intravitreal injections 60 platelet reactivity 60 FOLFIRI 60 bi ventricular pacing 60 schizophrenia CIAS 60 paroxysmal nocturnal hemoglobinuria PNH 60 Retisert TM 60 risperidone Risperdal 60 AEG# 60 cardiotoxic 60 rheumatoid arthritis psoriatic arthritis 60 GI motility disorders 60 LHON 60 Relapsing Remitting Multiple Sclerosis 60 coinfected patients 60 microbiological eradication 60 lapatinib Tykerb 60 interferon gamma 1b 60 retinal vein occlusion 60 lymphocytosis 60 polyarticular 60 AGGRASTAT ® tirofiban hydrochloride 60 leukotriene pathway 60 K ras mutations 60 trastuzumab Herceptin ® 60 sirolimus stent 60 prospective multicenter 60 Amiodarone 60 R Saizen R 60 IBS C 60 follicular lymphoma FL 60 μg dose 60 hypoparathyroidism 60 BR.# 60 CA4P 60 ventricular fibrillation VF 60 MADRS score 60 VTEs 60 ipsilateral stroke 60 CBLC# 60 IL 1ß 59 severe neutropenia 59 hyperglycaemia 59 ADVEXIN therapy 59 HF hospitalization 59 nab paclitaxel 59 Score TOS 59 simvastatin ezetimibe 59 multiple myeloma MM 59 cisplatin vinorelbine 59 Noxafil 59 azacytidine 59 mCRC patients 59 primidone 59 parecoxib 59 Vandetanib 59 TNF Tumor Necrosis Factor 59 etanercept 59 Aprotinin 59 tigecycline 59 aromatase inhibitors AIs 59 macrolide antibiotic 59 Lantus ® 59 DVT PE 59 cardiogenic shock 59 CHOP chemotherapy 59 elevated LDL cholesterol 59 postoperative chemotherapy 59 oral antiplatelet therapy 59 unresectable HCC 59 docetaxel Taxotere 59 mCRC 59 ticagrelor 59 serum phosphorous 59 trans retinoic acid 59 cutaneous T 59 CRVO 59 primary hypercholesterolemia 59 CYPHER ® 59 Phase IIIb 59 anti arrhythmic drugs 59 Clostridium difficile associated 59 abatacept 59 HER2 overexpression 59 telmisartan 59 brivaracetam 59 HuLuc# 59 prognostic variables 59 ara C 59 EGFR inhibitors 59 liposome injection 59 plus dexamethasone 59 proliferator activated receptor 59 Idiopathic pulmonary fibrosis 59 PEG interferon 59 cancer mCRC 59 carboplatin paclitaxel 59 IFN α 59 bosentan 59 antihypertensives 59 antiplatelet medications 59 macroalbuminuria 59 TNF antagonists 59 dosage regimens 59 FASLODEX 59 intravascular hemolysis 59 artery stenosis 59 Febrile neutropenia 59 binary restenosis 59 myelodysplastic syndromes 59 intravesical therapy 59 Aggrastat ® tirofiban hydrochloride 59 vorinostat 59 apremilast 59 Raptiva R 59 glatiramer acetate 59 Aloxi injection 59 ezetimibe simvastatin 59 Ischemic stroke 59 purpura ITP 59 achieved ACR# 59 syncopal 59 DES implantation 59 myeloproliferative diseases 59 RLAI 59 HMG CoA reductase inhibitors 59 REMINYL ® 59 Renal impairment 59 TAXUS VI 59 MDS MPD 59 LMWH 59 haematologic malignancies 59 VT VF 59 imetelstat 59 axitinib 59 APTIVUS R 59 alteplase 59 comparator arm 59 prespecified secondary 59 familial hypercholesterolemia 59 medullary thyroid cancer 59 C1 INH 59 methicillin resistant S. aureus 59 Peripheral neuropathy 59 anticoagulation therapy 59 sertraline Zoloft 59 LANTUS ® 59 moderately emetogenic 59 enzastaurin 59 fibrinolytic 59 etoposide 59 phase IIa clinical 59 pioglitazone HCl 59 virological failure 59 ABCB1 59 aromatase inhibitor AI 59 patientswith 59 carcinoid tumors 59 thiazolidinediones TZDs 59 gadobutrol 59 ICD implantation 59 MAGE A3 ASCI 59 Vidaza ® 59 neovascular 59 B CLL 59 #mg/day [001] 59 Ranolazine 59 acute HAE attacks